期刊
PHARMACEUTICALS
卷 13, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/ph13030038
关键词
[Ga-68]Ga-DOTA-TOC; positron emission tomography (PET); somatostatin receptor (SSTR); neuroendocrine tumors (NETs); theranostics
In the United States, [Ga-68]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first Ga-68-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [Ga-68]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide Ga-68 with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据